CHD7 (gene)

CHD7 (gene)
Name	CHD7
Other symbols	CHD7A
Locus	8q12
Gene type	protein-coding
OMIM	608892
HGNC	2151

CHD7 (gene) is a human protein-coding locus on chromosome 8q12 encoding chromodomain helicase DNA-binding protein 7, a member of the chromodomain helicase DNA-binding (CHD) family. The gene product functions as an ATP-dependent chromatin remodeler implicated in transcriptional regulation during embryonic development and tissue differentiation. Mutations in CHD7 are the primary cause of a multisystem developmental disorder and have been studied across genetics, developmental biology, and clinical medicine.

Function

CHD7 encodes a chromatin remodeler that uses ATP hydrolysis to alter nucleosome positioning, interacting with factors involved in transcription and development. In biochemical assays and proteomic studies CHD7 associates with components characterized in studies of SWI/SNF complex, Mediator complex, histone H3, RNA polymerase II, and remodeling modules described in research on BRG1, SNF2, and ISWI. Developmental genetics experiments link CHD7 activity to control of enhancers and promoters during organogenesis in contexts studied by investigators at institutions such as National Institutes of Health, Harvard University, and Wellcome Trust. Loss- and gain-of-function analyses align CHD7 function with pathways examined in research on SOX2, PAX6, TBX1, FGF8, and SHH.

Structure and Genomic Context

The CHD7 locus spans multiple exons on cytogenetic band 8q12 and encodes a protein of approximately 2,992 amino acids containing tandem chromodomains, a SNF2-like ATPase/helicase domain, and a C-terminal BRK domain. Structural features were mapped using approaches pioneered in cryo-electron microscopy studies at centers like Max Planck Society and European Molecular Biology Laboratory, and domain homology was inferred from alignments with proteins studied at Cold Spring Harbor Laboratory and Broad Institute. Genomic context analyses reference databases maintained by groups such as Ensembl, UCSC Genome Browser, and NCBI and integrate population variation datasets produced by consortia including the 1000 Genomes Project and Exome Aggregation Consortium.

Clinical Significance

Heterozygous CHD7 mutations are the predominant cause of CHARGE syndrome, a congenital condition characterized by coloboma, heart defects, choanal atresia, growth retardation and ear anomalies, first codified in clinical literature and reviewed in clinical centers including Mayo Clinic and Johns Hopkins Hospital. Pathogenic variants include truncating, missense, and splice-site mutations documented in clinical registries curated by organizations such as OMIM and disease networks collaborating with European Reference Networks. CHD7 variation has also been implicated in isolated presentations affecting craniofacial, auditory, and cardiac phenotypes investigated by specialists at institutions like Great Ormond Street Hospital and St. Jude Children's Research Hospital. Genetic counseling and diagnostic workflows reference guidelines developed by professional bodies including the American College of Medical Genetics and Genomics.

Molecular Mechanisms and Pathways

Mechanistically, CHD7 remodels chromatin at enhancer elements and collaborates with lineage-determining transcription factors to regulate gene expression programs. Studies connect CHD7 to pathways involving Notch signaling, WNT signaling pathway, Fibroblast growth factor, and nucleosome dynamics characterized in work led by laboratories at Stanford University and MIT. CHD7 influences epigenetic marks such as histone methylation and acetylation cataloged in epigenomics efforts by the ENCODE Project and the Roadmap Epigenomics Project. Interaction maps place CHD7 within networks that include developmental regulators like EYA1, SIX1, GATA3, and chromatin modifiers studied by investigators at Cold Spring Harbor Laboratory.

Expression and Regulation

CHD7 expression is developmentally regulated with high transcript and protein levels in neural crest derivatives, otic placode, eye primordium, and cardiac progenitors as documented by in situ hybridization and transcriptomic atlases produced by consortia such as Allen Institute for Brain Science and Human Cell Atlas. Transcriptional regulation of CHD7 involves promoter and enhancer architecture explored using techniques established at Massachusetts General Hospital and European Bioinformatics Institute, and post-translational regulation includes phosphorylation and ubiquitination processes researched in laboratories affiliated with Max Planck Institute. Alternative splicing and allele-specific expression patterns have been reported in population studies coordinated by GTEx and others.

Model Organisms and Experimental Studies

Model systems have been instrumental for CHD7 research: mouse knockouts and conditional alleles produced by groups at Jackson Laboratory recapitulate CHARGE-like phenotypes; zebrafish morphants analyzed by teams at University of Oregon and University of California, San Diego reveal otic and craniofacial defects; Xenopus and chick models used by investigators at University of Cambridge and University of Edinburgh probe neural crest migration. Functional studies using human induced pluripotent stem cells sourced from centers such as Stanford University enabled differentiation assays that implicate CHD7 in cardiogenesis, neurogenesis, and inner ear development. Experimental therapeutics and modifier screens have been explored in collaborative networks including Rare Diseases Clinical Research Network.

Category:Human genes